 GSK PLC LSE:GSK, NYSE:GSK has started for withdrawal process for US marketing authorisation for Blenrep following a request of the US Food and Drug Administration FDA. The request followed the previously announced outcome of the DREAMM-3 phase III trial which failed to meet FDA requirements wiping around 1.7bn of the FTSE 100 listed groups share price. 